Drugmakers Pfizer, BioNTech and Moderna are expected to reap billions of dollars from Covid-19 booster shots in a market that could rival the $6 billion in annual sales for flu vaccines for years to come, analysts and healthcare investors say.

Calling herself a “change agent,” GlaxoSmithKline Chief Executive Officer Emma Walmsley outlined plans to transform the pharmaceuticals business of GSK following the expected spin-off of the company’s consumer health division during an investor conference.

Amgen Inc. reported that third-quarter 2020 adjusted profit rose 17% due to stronger sales of drugs such as the osteoporosis treatment Prolia and the psoriasis medication Otezla, bucking challenges from lower drug prices and Covid-19.

The U.S. Justice Department charged Glenmark Pharmaceuticals with conspiring with other generic drug companies to increase and hold prices for the cholesterol drug pravastatin between May 2013 and December 2015.

AstraZeneca forecast sales growth for full-year 2019, driven by revenue from cancer medicines and other new treatments.

Teva Pharmaceutical Industries Ltd. revenue in the second quarter of 2018 were $4.7 billion – a decrease of 18%, or 19% in local currency terms – compared to the second quarter of 2017, mainly due to continued price erosion in our U.S. generics business.

Regeneron Pharmaceuticals Inc. reported important commercial progress in the second quarter with continued strong U.S. sales growth for Eylea in retinal diseases and Dupixent in atopic dermatitis.

Novartis is halting planned price increases on the Swiss pharma giant’s medications after President Donald Trump took Pfizer to task over price hikes, with Pfizer subsequently agreeing to roll back the company’s price increases.

Sage Therapeutics, located in Cambridge, Mass., submitted a New Drug Application to the U.S. Food and Drug Administration for brexanolone (SAGE-547) to treat postpartum depression.

Fears of the demise of blockbuster eye drug Eylea were “greatly exaggerated,” Regeneron Pharmaceuticals Inc.’s chief executive said after the treatment and new eczema drug Dupixent powered the company’s fourth-quarter 2017 results.